Description of exendin-3(939) amide, a specific exendin receptor antagonist
In a Phase 2 dose-ranging trial, participants receiving the highest tested dose (12 mg once weekly) experienced an average weight reduction of about 24.2% at 48 weeks
Maintaining weight loss after GLP-1s depends on long-term habits that lower carbohydrate intake, increase physical activity, and manage stress
This triple action on GIP, GLP-1, and glucagon receptors creates stronger appetite suppression and greater metabolic effects than single or dual agonist peptides
days 1 to 30): 3 mg orally once a day Dose escalation (days 31 to 60): 7 mg orally once a day Maintenance dose (day 61 and onward): If no additional glycemic control is needed: 7 mg orally once a day If additional glycemic control is needed: 14 mg orally once a day SUBCUTANEOUS: Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: 0.5 to 2 mg subcutaneously once a week, based on glycemic control If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose: Increase to 1 mg subcutaneously once a week
Being able to visit a real office, speak directly with a team, and know where to turn if questions come up can make the experience feel more personal and reassuring
